Non-steroidal anti-inflammatory drugs induced toxic epidermal necrolysis
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250944Keywords:
Toxic epidermal necrolysis, NSAIDs, SCORTEN score, AKIAbstract
This case report presents a 48-year-old woman with a history of chronic kidney disease who experienced toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, an uncommon and severe adverse drug reaction. The TEN was attributed to the use of non-steroidal anti-inflammatory drugs (NSAIDs). Cutaneous involvement exceeded 80% of the body surface area (BSA), encompassing ocular, oral, and nasal mucosa, as well as the trunk, bilateral limbs, and genitalia. Treatment commenced with aggressive fluid resuscitation, the administration of cyclosporine, and meticulous dermal care. The patient was ultimately discharged following approximately one month of intensive therapy.
Metrics
References
Hoetzenecker W, Mehra T, Saulite I, Glatz M, Schmid-Grendelmeier P, Guenova E, et al. Toxic epidermal necrolysis. F1000Research. 2016;5:F1000. DOI: https://doi.org/10.12688/f1000research.7574.1
Lin CC, Chen CB, Wang CW, Hung SI, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Rev Clin Immunol. 2020;16(4):373-87. DOI: https://doi.org/10.1080/1744666X.2020.1740591
Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Academy Dermatol. 2007;56(2):181-200. DOI: https://doi.org/10.1016/j.jaad.2006.04.048
Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Research. 2020;9. DOI: https://doi.org/10.12688/f1000research.24748.1
Neagu TP, Tiglis M, Peride I, Niculae A. Toxic Epidermal Necrolysis, A Serious Side Effect of Tenoxicam Use: A Case Report. InHealthcare 2023;11(15):2195. DOI: https://doi.org/10.3390/healthcare11152195
Mockenhaupt M, Kelly JP, Kaufman D, Stern RS, SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30(10):2234-40.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Academy Dermatol. 2013;69(2):173-e1. DOI: https://doi.org/10.1016/j.jaad.2013.05.003
Kannappilly N, Peediyakkal MZ, Khatib MY, Ananthegowda DC, Elshafei MS, El Zeer H, et al. Ibuprofen-Induced Toxic Epidermal Necrolysis: A Case Report. Int J Dermatol Venereol. 2024;7(2):108-10. DOI: https://doi.org/10.1097/JD9.0000000000000249
Melezović I, Mehmedagić S, Begić E, Mekić M, Čvorak E. Ibuprofen–induced toxic epidermal necrolysis–A CASE REPORT. Reumatizam. 2022;69(2):117-23. DOI: https://doi.org/10.33004/reumatizam-69-2-5
Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633-8. DOI: https://doi.org/10.1159/000195632
Charlton OA, Harris V, Phan K, Mewton E, Jackson C, Cooper A. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care. 2020;9(7):426-39. DOI: https://doi.org/10.1089/wound.2019.0977
Harris V, Jackson C, Cooper A. Review of toxic epidermal necrolysis. Int J Molecular Sci. 2016;17(12):2135. DOI: https://doi.org/10.3390/ijms17122135
Fernando SL. The management of toxic epidermal necrolysis. Aus J Dermatol. 2012;53(3):165-71. DOI: https://doi.org/10.1111/j.1440-0960.2011.00862.x
Downloads
Published
How to Cite
Issue
Section
